An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed with a no-effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure), respectively.
25 vastavalt toimeta annuse 500 mg/ kg (59- kordne inimesel saavutatav ekspositsioon) ja 100 mg/ kg (16- kordne inimesel saavutatav ekspositsioon) puhul.